Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE: 002821)
Health Care · Pharmaceuticals · CN
CN¥168.10
-1.81% today · +52.0% 1Y
Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE: 002821) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $8.72B and employs 10,617 people.
Over the last twelve months the share price has gained 52.0%, trading between 88.46 and 200.00.
Tweenvest scores Asymchem Laboratories (Tianjin) Co., Ltd. across four factors: quality 71/100, value 24/100, growth 71/100, dividend 26/100. Its strongest factor is quality.
002821 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $8.72B
- Revenue (TTM)
- $1.00B
- P/E
- 54.09
- EPS
- 3.11
- Dividend yield
- 0.77%
- Beta (5Y)
- 0.12
- 52-week high
- CN¥200.00
- 52-week low
- CN¥88.46
- Avg volume (3M)
- —
- Shares outstanding
- 359.63M
- Employees
- 10,617
- Next earnings
- —
About Asymchem Laboratories (Tianjin) Co., Ltd.
Asymchem Laboratories (Tianjin) Co., Ltd. functions as a contract development and manufacturing organization (CDMO), offering its expertise to pharmaceutical and biotechnology companies both globally and within Mainland China. Their services encompass drug research, development, and production, supporting projects across the entire drug lifecycle, from early clinical phases to commercial scale. This includes R&D and cGMP-compliant manufacturing of advanced intermediates, active pharmaceutical ingredients (APIs), and finished drug formulations, in addition to providing clinical research support. Furthermore, Asymchem engages in pharmaceutical analysis and testing, the distribution (wholesale, retail, and direct sale) of medicines, and initiatives focused on advancing pharmaceutical science and technology. The company, established in 1999, maintains its headquarters in Tianjin, China.
- ISIN
- CNE100002BZ6
- Founded
- 1998
- Listed since
- Nov 22, 2016
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.